Skip to main contentSkip to navigationSkip to search
Curasight

Press releases

2021

Curasight A/S presents at Økonomisk Ugebrev Life Science Investor Conference in Copenhagen 20 October 2021

October 15, 2021
 | Regulatory
Curasight A/S CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company and its future plans at Økonomisk Ugebrev Life Science Investor Conference in Copenhagen 20 October 2021, 15:10 (CET).

Curasight A/S presents at BioStock Life Science Summit 20 October 2021

October 15, 2021
 | Regulatory
Curasight A/S CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company and its future plans, at BioStock Life Science Summit 20 October 2021, 13:20 (CET).

Curasight A/S warrant exercise registered at Erhvervsstyrelsen

October 13, 2021
 | Regulatory
On Thursday, 7 October 2021, the exercise period for Curasight A/S (“Curasight” or “the Company”) warrants of series TO 1 (“TO 1”) ended. The warrant exercise has now been registered at Erhvervsstyrelsen. The total number of registered shares now amounts to 19,893,891 shares and the share capital amounts to DKK 994,694.55. The conversion from interim shares to ordinary shares will be made on Friday, 15 October 2021, and new shares are expected to be in each of the shareholders’ accounts around Monday, 18 October 2021.

Curasight A/S receives approximately DKK 47.6 million through exercise of warrants of series TO 1

October 11, 2021
 | Regulatory
On Thursday, 7 October 2021, the exercise period for Curasight A/S (“Curasight” or “the Company”) warrants of series TO 1 (“TO 1”) ended. A total of 2,767,551 warrants of series TO 1 were exercised. Curasight will thus receive a total of approximately DKK 47.6 million before issue costs.

Curasight warrant TO 1 – last day of trading is Tuesday 5 October 2021

September 30, 2021
 | Regulatory
Tuesday, 5 October 2021, is the last day of trading in warrants of series TO 1 on Spotlight Stock Market. The warrant TO 1 was issued in connection with Curasights A/S (“Curasight” or “the Company”) IPO in 2020. The last day to subscribe for shares with the support of warrants of series TO 1 is 7 October 2021.

Transactions with warrants of series TO 1 in Curasight A/S made by managerial employees and their closely associated persons

September 21, 2021
 | Regulatory
COPENHAGEN – Curasight A/S (“Curasight” or “the Company”).  In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Curasight made by managerial employees and their closely associated persons. 

The Company’s managerial employees and their closely associated persons have given Curasight’s power of attorney on their behalf to publish trading in Curasight’s warrants of series TO 1 by the Company’s managerial employees and their closely associated persons. Curasight’s managerial employees and their closely associated persons have exercised all their warrants of series TO 1.

The exercise period for warrants of series TO 1 in Curasight A/S begins today

September 16, 2021
 | Regulatory
Today, 16 September, 2021, marks the beginning of the exercise period for the warrants of series TO 1 that were issued in connection with Curasight A/S (“Curasight” or “the Company”) issue of units during September 2020. The exercise period runs until and including 7 October, 2021. Upon full exercise of all warrants, Curasight will receive approximately DKK 48.8 million (before issue costs). Sedermera Fondkommission is the financial adviser and Markets & Corporate Law Nordic AB is the legal advisor in connection with the warrant exercise. Nordic Issuing is the issuing agent.

Curasight A/S strengthens its institutional investor base

September 1, 2021
 | Regulatory
Copenhagen, Denmark, 1 September 2021 – Curasight A/S (“Curasight” or the “Company”) has strengthened its institutional investor base as part of the company's future strategy. Arbejdernes Landsbank has today acquired 200,000 warrants from the Swedish investment company Eastbridge, which is already a strategic investor in Curasight.

Interim report January – June 2021

August 24, 2021
 | Regulatory
Curasight A/S (“Curasight” or the “Company”) hereby publishes the interim report for the period January 1 – June 30, 2021. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Curasight presents at HC Andersen Capital

August 23, 2021
 | Regulatory
Curasight A/S (“Curasight” or the “Company”) CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the Interim Report First Half 2021 at HC Andersen Capital, 24 August 2021.
Load more